TITLE

Cancer therapy finds a solid target

AUTHOR(S)
Secko, David
PUB. DATE
August 2005
SOURCE
CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p246
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on a study conducted by Roberto Chiarle and colleagues which points the finger at the oncogene signal transducer and activator of transcription 3 (STAT3) as a promising target for the development of a broad anticancer therapy. Information on STAT3; Role played by STAT3 in the development of anaplastic large-cell lymphomas; Methodology used by the researchers to determine if blocking the activation of STAT3 could have a therapeutic effect.
ACCESSION #
17679324

 

Related Articles

  • Will we cure cancer by sequencing thousands of genomes? Nicholson, Joshua M. // Molecular Cytogenetics (17558166);2013, Vol. 6 Issue 1, p1 

    The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide...

  • Assessment and modulation of chemoresistance by different sub-groups of chemosensitizers in a NHL cell line model. Foroutan, Behzad; Anderson, Diana // Basic & Clinical Cancer Research;2011, Vol. 3 Issue 3/4, p15 

    Background: The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as Non-Hodgkin's Lymphoma (NHL). With the recognition of important roles for both p53 and its more recently described paralog p73 in mediating the activity of anti-cancer drugs,...

  • IL10 receptor is a novel therapeutic target in DLBCLs. B├ęguelin, W; Sawh, S; Chambwe, N; Chan, F C; Jiang, Y; Choo, J-W; Scott, D W; Chalmers, A; Geng, H; Tsikitas, L; Tam, W; Bhagat, G; Gascoyne, R D; Shaknovich, R // Leukemia (08876924);Aug2015, Vol. 29 Issue 8, p1684 

    Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease with marked genomic instability and variable response to conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. More clinically aggressive cases of...

  • Gene Defective in at Least 50-60 Percent of All Prostate Cancers; Find Key Step in Understanding Basis of This Cancer.  // Ascribe Newswire: Medicine;12/20/2001, p1 

    At least 50 to 60% of all prostate cancers are the result of failure of just one gene, according to a study by researchers at Mount Sinai School of Medicine, published in the December 20, 2001 issue of the journal "Science." This discovery opened the way for the possibility of new means of early...

  • Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy. Sawyer, Tomi K. // Current Medicinal Chemistry - Anti-Cancer Agents;Sep2004, Vol. 4 Issue 5, p449 

    Small-molecule drug discovery for cancer therapy is making extraordinary progress within the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of significant impact to both basic research and clinical testing. In this perspective, structure- and mechanism-based drug...

  • Targeting the oncogene eIF4E in cancer: From the bench to clinical trials. Borden, Katherine L. B. // Clinical & Investigative Medicine;Dec2011, Vol. 34 Issue 6, pE315 

    Identifying and targeting specific oncogenes, with the hope that the resultant therapies may eventually prove to exert positive clinical effects, is a major effort in the area of cancer therapeutics. The eukaryotic translation initiation factor, eIF4E, is overexpressed in many cancers, including...

  • The second wave in kinase cancer drugs. Garber, Ken // Nature Biotechnology;Feb2006, Vol. 24 Issue 2, p127 

    The article discusses the efficacy of new generation protein kinase inhibitors for treating cancer. The latest advances in molecular oncology have enable pharmaceutical companies to develop more potent kinase inhibitors. Researchers believe that the inhibition of kinases could also curtail the...

  • Oncogenes, tumor suppressors and p52 NF-?B. Perkins, Neil D // Oncogene;10/23/2003, Vol. 22 Issue 48, p7553 

    A role for the p52 NF-?B subunit in tumorigenesis has been steadily emerging since its discovery as a gene associated with chromosomal translocations in B- and T-cell lymphomas. Now Eliopoulos and co-workers have extended these studies to examine the effect of the Epstein-Barr virus...

  • Targeting oncogenes. Goodman, Laurie // Journal of Clinical Investigation;Nov2004, Vol. 114 Issue 10, p1362 

    The article reports that a single change to the myriad alterations in a tumor, inactivating the Myc oncogene, resulted not only in inhibition of tumor growth but also in tumor regression. Transgenic mice were generated that conditionally express the Myc oncogene in a cell-specific manner. Myc...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics